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ABSTRACT
Chronic kidney disease (CKD) is often associated with a mineral and bone disorder globally described as CKD-Mineral and
Bone Disease (MBD), including renal osteodystrophy, the latter ranging from high bone turnover, as in case of secondary
hyperparathyroidism (SHPT), to low bone turnover. The present article summarizes the important subjects that were
covered during ‘The Parathyroid Day in Chronic Kidney Disease’ CME course organized in Paris in September 2017. It
includes the latest insights on parathyroid gland growth, parathyroid hormone (PTH) synthesis, secretion and regulation by
the calcium-sensing receptor, vitamin D receptor and fibroblast growth factor 23 (FGF23)–Klotho axis, as well as on
parathyroid glands imaging. The skeletal action of PTH in early CKD stages to the steadily increasing activation of the often
downregulated PTH receptor type 1 has been critically reviewed, emphasizing that therapeutic strategies to decrease PTH
levels at these stages might not be recommended. The effects of PTH on the central nervous system, in particular cognitive
functions, and on the cardiovascular system are revised, and the reliability and exchangeability of second- and third-
generation PTH immunoassays discussed. The article also reviews the different circulating biomarkers used for the
diagnosis and monitoring of CKD-MBD, including PTH and alkaline phosphatases isoforms. Moreover, it presents an update
on the control of SHPT by vitamin D compounds, old and new calcimimetics, and parathyroidectomy. Finally, it covers the
latest insights on the persistence and de novo occurrence of SHPT in renal transplant recipients.
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INTRODUCTION
Chronic kidney disease (CKD) is often associated with a mineral
and bone disorder globally described as CKD-Mineral and Bone
Disease (MBD), including renal osteodystrophy (ROD), the latter
ranging from high-turnover bone diseases such as in secondary
hyperparathyroidism (SHPT), with its extreme and severe mani-
festation osteitis fibrosa, to low-turnover bone diseases such as
osteomalacia and adynamic bone disease. Serum parathyroid
hormone (PTH) is a recognized marker of bone remodelling in
patients with ROD. However, identification of N-terminal trun-
cated PTH fragments, oxidized PTH and new forms of PTH, which
interfere with PTH assays and may be responsible for the great
variability of PTH values in CKD, gave rise to the wide range of
the PTH targets suggested by Kidney Disease: Improving Global
Outcomes (KDIGO) [1]. Despite the fact that its importance in CKD
has been recognized for decades, insight on PTH measurement,
clinical relevance and modes of action still evolve. To provide an
update on these most recent developments the ERA-EDTA work-
ing group on CKD-MBD organized ‘The Parathyroid Day in
Chronic Kidney Disease’. This was a continuous medical educa-
tion (CME) course organized in Paris in September 2017. In this re-
port, we provide a summary of key aspects with special focus on
important novel insights, preceded by a brief review of estab-
lished knowledge in a historical perspective.
PARATHYROID GLANDS IN CKD—ANATOMY,
HISTOLOGY, PHYSIOLOGY ANDMOLECULAR
BIOLOGY IN CKD
Most frequently, humans have four parathyroid glands. They
are variably located on the back of the upper and lower poles of
the thyroid gland. However, 20% of people have five parathy-
roid glands, and a few have even six glands, often in ectopic
locations. The identification of aberrant parathyroid glands by
imaging methods and during neck exploration in case of surgi-
cal parathyroidectomy (PTX) often proves extremely difficult.
The parathyroid tissue is composed of two main secretory cell
types, namely chief cells and oxyphil cells. The synthesis and
secretion of PTH are regulated by numerous factors. Besides cal-
cium, which is the most important regulator, calcitriol, phos-
phate, fibroblast growth factor 23 (FGF23), a-Klotho, PTH itself
and PTH-related peptide (PTHrP), as well as their respective
receptors, all participate in this process [2]. Additional modula-
tion occurs at the posttranscriptional level via mRNA stabilizing
protein AU rich binding factor 1 [3] and differential expression of
miRNAs [4]. The physiological control of PTH synthesis and secre-
tion is progressively lost with the progression of CKD, as a conse-
quence of changes in the circulating levels and/or parathyroid
tissue expression of these regulators, and also disturbances of he-
patic and renal PTH catabolism. In parallel with a chronic stimu-
lation of PTH secretion the parathyroid tissue undergoes an
increase in parathyroid cell proliferation (hyperplasia), also due
to the above PTH changes in regulators and the recently discov-
ered mechanistic target of rapamycin complex 1 pathway activa-
tion [5]. Although a higher apoptosis rate occurs concomitantly,
this is unable to compensate for the excessive cell growth [6]. The
combined result is the well-known SHPT of CKD. Although ini-
tially the hyperplasia is of polyclonal nature and considered to be
reversible its growth pattern generally changes from polyclonal
to monoclonal or multiclonal proliferation when the SHPT
becomes severe [7]. On light microscopy examination, it is char-
acterized by nodular transformation of the parathyroid gland,
suggesting the presence of one or several benign tumours. The
clonal proliferation is due to loss of tumour growth inhibitory
genes and/or gain of tumour growth promoter genes, as reflected
by chromosomal gains and losses using comparative genomic
hybridization and genome-wide molecular allelotyping techni-
ques [8]. Clinically, clonal parathyroid cell growth probably indu-
ces a state of relative resistance to PTH-lowering treatments.
Moreover, such benign tumours do not regress after renal trans-
plantation despite the restoration of near normal or at least
greatly improved kidney function and give rise to so-called per-
sistent hyperparathyroidism as discussed below.
CaSR AND PTH RECEPTOR IN CKD
The extracellular calcium-sensing receptor (CaSR) was first de-
scribed in the parathyroid gland [9]. It is a 121-kDa protein that
plays a crucial role in Ca homeostasis, in particular via a tight
control of the extracellular ionized calcium concentration. It
belongs to class C of the G-protein-coupled membrane-bound
receptor superfamily. At the cell surface, the CaSR is present
constitutively in a dimeric configuration. This homodimerized
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configuration is crucial for its normal function. Recent studies
have shown that the CaSR is also expressed in the cardiovascu-
lar system but our understanding of its physiological functions
in this system remains incomplete [10]. Inactivating CaSR muta-
tions lead to familial hypocalciuric hypercalcaemia or neonatal
severe hyperparathyroidism and activating mutations to auto-
somal dominant hypocalcaemia. In CKD, decreased parathyroid
CaSR expression participates in the pathogenesis of SHPT [11].
Several factors are probably involved in this decrease, including
uremic toxins. Calcimimetics have been demonstrated to be
particularly useful in controlling PTH hypersecretion and con-
comitantly reducing serum calcium and phosphate levels in di-
alysis patients. Recent findings also point to the role of CaSR
allosteric coactivators as inhibitors of the development of vas-
cular calcification not only by correcting PTH hypersecretion,
but also by directly modulating vascular CaSR activity [12].
PTH binds to PTH/PTHrP receptor type 1 (PTH1R), which is
expressed in numerous tissues including kidney and bone and
activates several intracellular second messengers [13]. Activation
of PTH1R reduces serum phosphate by decreasing its renal reab-
sorption. It also increases calcitriol production by its stimulatory
effect on renal 25-hydroxy vitamin D (25OHD)–1a-hydroxylase ac-
tivity. PTH1R is highly expressed the primary target organs for
PTH, kidney and bone, and at relatively lower levels in the vascula-
ture [14]. In addition to PTH1R, a second G protein-coupled PTH re-
ceptor, PTH2R, of uncertain physiological significance has been
identified [15]. Finally, a receptor with specificity for the C-terminal
region of PTH (C-PTHR) has been identified, but not yet fully char-
acterized, in osteoblasts and osteocytes [16]. Available evidence
suggests that it acts antagonistically to the PTH/PTH1R system.
End-organ hyporesponsiveness to PTH, formally referred to as PTH
resistance, has long been recognized in CKD. It is attributed, at
least partially, to downregulation or desensitization of PTH1R [17].
Factors such as phosphate, indoxyl sulphate and paracresyl sul-
phate accumulation may play a role in this phenomenon [18].
Hyporesponsiveness to the skeletal action of PTH in early CKD
stages could explain observations of a relatively high prevalence of
low bone turnover disease, predominantly adynamic bone disease.
An early inhibition of the Wnt pathway with an increase in the ex-
pression of sclerosis and other inhibitors of Wnt signalling may be
involved. With the progression of CKD to more advanced stages
and more severe SHPT, the steadily increasing activation of PTH1R
eventually overcomes the skeletal resistance to the action of PTH,
and osteitis fibrosa or mixed ROD ensue, if left untreated.
KLOTHO–FGF23–PTH AXIS IN CKD
The physiological role of FGF23, in particular its effect on renal
phosphate handling, and its associations with dismal outcomes in
CKD is well established and beyond the scope of this report [19].
In parathyroid glands, FGF23 downregulates PTH secretion,
principally through the classic Klotho-dependent pathway of
mitogen-activated protein kinases (MAPK) activation, or sec-
ondarily through the less-explored phospholipase C gamma
(PLCc)-dependent activation of the nuclear factor of activated T-
cells (NFAT) cascade [20]. In fact, recent data suggest that in ad-
dition to CaSR and vitamin D receptor activation, the FGF23–
Klotho endocrine axis suppresses PTH secretion. In parathyroid
tissue, FGF23 binds to the cell membrane-located FGF receptor–
Klotho complex to elicit activation of the MAPK-pathway, but it
can also act in absence of Klotho via a phosphoinositide-
specific PLCc-dependent activation of the NFAT pathway.
Available evidence suggests that a positive phosphate balance
occurs even in still normo-phosphataemic CKD patients,
secondary to reduced glomerular filtration rate (GFR). These events
are thought to trigger both PTH and FGF23 increments to counter-
balance phosphate overload [21]. FGF23 resistance, resulting from
progressively reduced Klotho expression in kidney and parathyroid
gland tissue with the progression of CKD, further enhances FGF23
synthesis and increased circulating FGF23 levels [19, 21].
SHPT is a common consequence of CKD. Initially, this condi-
tion may seem counterintuitive, considering that FGF23 inhibits
PTH secretion. Currently, the most reasonable explanation for
SHPT in CKD patients is resistance of parathyroid tissue to the
action of FGF23, particularly in cases with extremely high FGF23
levels. This hypothesis is supported by reduced Klotho and FGF
receptor expression observed in surgically resected human hy-
perplastic parathyroid glands [22].
PTH, CNS AND COGNITIVE FUNCTIONS
In addition to their roles in the periphery, it has been shown
that many hormones, which include insulin, leptin, thyroid hor-
mone, sex steroid hormones, glucocorticoids and osteocalcin,
can also influence the central nervous system (CNS), regulate
brain development, modulate cognitive functions and strongly
influence the central regulation of whole-body energy balance
[23–31]. Importantly, increasing evidence suggests that changes
in their circulating levels may contribute to age-related cogni-
tive decline, as well as to the development of neurodegenerative
diseases [32, 33]. While the impact of the hormones on brain
functions, both in normal and ageing conditions, is undeniable,
the influence of many of them on brain cognitive functions still
remains to be explored. A better understanding of the influence
of hormonal homeostasis in brain metabolic and cognitive ac-
tivities may open up new roads for therapeutic intervention to
ameliorate disease-related cognitive impairments, and reverse/
prevent age-related memory decline.
Interestingly, numerous studies have reported that the age-
induced increase in PTH levels is associated with higher risk of
cognitive decline and incident dementia [34, 35]. Moreover, ob-
servational studies have described impaired cognitive functions
such as memory and attention tasks in patients with primary
hyperparathyroidism (PHPT) in the presence or even absence of
hypercalcaemia. These disturbances can be significantly im-
proved after surgical intervention normalizing PTH levels [36–
38]. SHPT, which is generally characterized by high serum PTH
levels with normal to low calcium levels as occurs in CKD, is
also associated with cognitive impairment, followed by the
same postoperative improvement [37, 39–41]. However, little is
known about the mechanisms linking PTH and cognition
impairments, both in HPT and in ageing populations.
Several hypotheses have been proposed to explain the associa-
tion between high PTH levels and cognitive deficits. Impaired cog-
nition in primary HPT has been traditionally attributed to
hypercalcaemia [42]. High serum calcium levels have been associ-
ated with faster decline in cognitive function, neuronal signalling
disruption or atrophy in hippocampus and Alzheimer’s disease,
frontal-subcortical dementia. Furthermore, PTH also promotes the
conversion of vitamin D to its active form (1, 25-dihydroxy vitamin
D), which an emerging body of evidence suggests may be neuro-
protective. However, based on the fact that PTH crosses the blood–
brain barrier [43–45] and that PTH receptors (Figure 1) are highly
expressed in human and rodent brains [14, 46–48], it is legitimate
to ask whether PTH signalling may also exert direct actions on the
CNS. Further neuropsychological investigations of cognitive func-
tions in patients with PHPT or age-related dementia, which include
confounding factors such as altered serum calcium, phosphate
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and vitamin D sterol levels and the examination of a possible di-
rect role of PTH in the CNS, are clearly warranted.
PTH MEASUREMENT IN CKD PATIENTS
PTH measurement is very important for the follow-up of
patients with CKD, in particular more advanced CKD. PTH deter-
mination represents the paradigm of quality in laboratory medi-
cine as many variables in the pre-, intra- and post-analytical
phases strongly affect the value of the clinical information. PTH
circulates as a 1-84 amino acids bioactive peptide, but its analyt-
ical determination is difficult because of the presence, in the cir-
culation, of N-terminal truncated fragments [called non-(1-84)
PTH] that tend to accumulate in CKD patients [49]. These frag-
ments also have a longer half-life compared with the 1-84 PTH.
Basically, two types of assays are present on the market: sec-
ond-generation (or ‘intact’ PTH: PTH2) and third-generation
assays (PTH3). PTH2 recognize the non-(1-84) PTH fragments
whereas PTH3 assays do not (Figure 2). PTH determination lacks
standardization, despite an International World Health
Organization Standard (IS 95/646) being available. Also, no refer-
ence method is available yet for PTH measurement. Hence,
results provided by the different assays are very different, espe-
cially in CKD patients [50]. Since the fragments cross-react dif-
ferently with the antibodies used in PTH2 assays, a full
standardization of PTH will only be possible with PTH3 assays.
It has been shown, however, that mathematical factors could
help to improve comparability of PTH results [51], but this is not
consistent over time and is a lower quality solution. Another
problem with PTH is the reference range (RR). Indeed, healthy
subjects selected for RR establishment need to be free of SHPT
and PHPT [52]. Hence, 25OHD, calcium and creatinine measure-
ments need to be performed prior to enrolment. Unfortunately,
most manufacturers have not performed such determinations
when establishing the RR, rendering those inaccurate. For in-
stance, up to 18% of PTH values are not comprised within the
RR we correctly established with the Roche PTH2 assay and the
manufacturer’s RR, and most of these cases actually presented
25OHD values far greater than 30 ng/mL. The KDIGO target
range for patients with dialysis-dependent CKD (2–9 upper
limit of normal) will also be differently classified, according to a
correctly established RR. Manufacturers’ RR and our own stud-
ies have shown that using a correctly established RR improves
patient classification according to KDIGO guidelines [53].
Besides these issues, PTH can be oxidized on its two methionine
amino acids, on Positions 8 and 18. It has been shown that oxi-
dized PTH is biologically inactive. PTH2 and PTH3 assays recog-
nize both oxidized (ox-PTH) and non-oxidized PTH (n-oxPTH).
Measurement of n-oxPTH alone needs a pretest capture of ox-
PTH by a specific antibody and subsequent measurement of
PTH by a PTH2 assay. Since important oxidative stress is present
in CKD patients, it has been hypothesized that PTH2 and PTH3
assays do not accurately measure bioactive PTH, but mostly oxi-
dized, inactive PTH. It has indeed been shown that n-oxPTH
may reflect more precisely the true hormone status and not the
risk of mortality. The increased mortality risk associated with
PTH might be reflecting an oxidative stress-related mortality
[54] as recently observed by Seiler-Mussler et al. [55] These find-
ings must however be confirmed by further studies.
Well recognized physiological roles New and less recognized roles
PTH
- Calcium
- Phosphate
- 1,25OH2D3
- Resorption
- Formation
- Cognitive fonction
- Energy balance
- LVH
- Heart failure
- Valves calcification
- Calcification
- HTA
- Hematopoiesis
- Immune system
- Carbohydrate,  protein and fat metabolism
- Drug metabolism
FIGURE 1: A possible role of PTH signalling in the brain. PTH is a major regulator of the calcium/phosphate balance in the body through its actions on bone and kidney.
PTH can bind and activate at least two receptors that belong to the G protein-coupled receptor family, PTH1R and PTH2R; however, its principal functions are associ-
ated with the first one. Importantly, these receptors are expressed in the CNS and may also bind paracrine ligands such as PTHrP for PTH1R and Tip 39 for the PTH2R.
These findings and the observation that patients with PHPT and SHPT often have memory loss and loss of appetite suggest a direct effect of PTH on the CNS.
4 | P.A. Ure~na-Torres et al.
Downloaded from https://academic.oup.com/ckj/advance-article-abstract/doi/10.1093/ckj/sfy061/5056879
by guest
on 21 July 2018
BONE METABOLIC MARKERS IN CKD PATIENTS
Bone markers reflect the activities of bone cells. They are di-
vided into two subgroups; humoral factors derived from bone
cells, and factors associated with type-I collagen metabolism. Of
the bone cell-derived factors, those secreted by osteoclasts are
regarded as bone resorption markers, and those originating
from osteoblasts are regarded as bone formation markers, ex-
cept for under-carboxylated osteocalcin, which also reflects vi-
tamin K status.
Bone remodelling is the lifelong process by which mature
bone is removed and new bone is formed; it is also the mecha-
nism allowing skeletal growth, bone reshaping and the replace-
ment of injured bone following fractures and micro-damages.
Bone remodelling is also crucial for the regulation of circulating
calcium and phosphate levels. Dialysis patients display ex-
tremely high risk of hip fracture [56–58]. Nevertheless, modern
clinical studies repeatedly demonstrated that PTH levels show
only a limited association with hip fracture risk [56, 57, 59, 60].
Bone markers roughly and noninvasively estimate activities
of bone cells and the degree of bone remodelling. The significance
of bone markers may be close to that of PTH action on bone, since
PTH is the most crucial determinant of bone remodelling fre-
quency. In fact, PTH itself is regarded as one of the most reliable
bone turnover markers in dialysis patients. However, bone me-
tabolism is no longer considered identical to bone cell metabo-
lism in modern bone biology. Bone extracellular material
metabolism can be independent from bone cell metabolism, and
recent studies revealed that bone material properties, i.e. bone
biochemical characteristics rather than bone remodelling fre-
quency, are the critical determinant of bone strength in uraemic
condition [61, 62]. Most of the bone markers including PTH do not
give information about these features, nor does bone histology
examination. Although bone histomorphological analysis is the
only way to establish a histological diagnosis, this is also the only
information such a bone biopsy can provide. Moreover, estimat-
ing bone histology by the level of circulating bone markers
remains of limited accuracy.
FIGURE 2: PTH measurements. PTH circulates as a bioactive 1-84 peptide (A), together with large N-truncated fragments called non-(1-84) PTH (B) and truncated frag-
ments (D). A form called amino-PTH corresponds to a 1-84 PTH containing a phosphorylated serine in Position 17 (C). ‘Intact’ PTH assays recognize the bioactive pep-
tide, but also the non-(1-84) PTH. Third-generation PTH assays use an antibody targeted against the first four amino acids of PTH and recognizes the bioactive peptide,
but not the non-(1-84) PTH. PTH can be oxidized on the methionine in Positions 8 and 18 and both third- and second-generation PTH assays recognize it. To measure
the non-oxidized PTH, a pretreatment of the sample with an antibody targeted against the oxidized PTH is needed, before determination with a second-generation
PTH assay.
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Total serum alkaline phosphatase (tAP) level showed tight
associations with hip fracture risk as well as mortality in dialy-
sis patients [63]. Its level may not totally represent bone remod-
elling because serum PTH level showed no relation to it.
However, this assumption should be taken with caution be-
cause the lack of correlation between tAP and PTH may be due
to the inaccuracies of PTH determination as above described.
Arterial ‘osteonization’, commonly called Mo¨nckeberg-type vas-
cular calcification, in which vascular smooth muscle cells dis-
play osteoblast-lineage like phenotype, is frequently observed
among dialysis patients. Since serum AP level represents the
number of osteoblasts and osteoblast-like cells, it may reflect,
at least partially, the development of this disease condition.
DELETERIOUS EFFECTS OF PTH ON THE HEART
PTH—among others—is a prototypic factor linking bone disease
to cardiovascular disease, since PTH affects not only this physi-
ological target organ, but also exhibits major ‘off-target’ effects
in the cardiovascular system. Noteworthy, numerous cohort
studies reported significant and independent associations be-
tween serum PTH levels and adverse outcomes including mor-
tality [64]. It is important to mention that the association
between PTH and outcome is not linear but J-shaped, suggesting
an ‘optimal PTH’ range for these specific outcomes, which could
be 150–300 pg/mL in dialysis patients [65]. Not only end-stage
renal disease (ESRD) patients but also cohorts of primarily cardi-
ology patients confirm the independent association between
PTH and clinical outcome [66].
Left ventricular hypertrophy (LVH) is among the major con-
tributing factors to morbidity and mortality in CKD and ESRD
patients. LVH is driven by several factors among which PTH is a
prominent one. A causal link between the two may exist by
the stimulatory actions of PTH upon the renin–angiotensin–
aldosterone system (RAAS) leading to increased levels of angio-
tensin II and aldosterone, which in turn cause LV remodelling
and arterial hypertension [67]. Data from a meta-analysis of
PTX effects upon LVH support the hypothesis of a causal link
between PTH and LVH since LVH regressed in most patients
with PHPT after surgery [68]. Underlying mechanisms may be
(i) PTH-induced specific vascular pathology such as endothelial
dysfunction and atherosclerosis; or (ii) direct detrimental myo-
cardial effects by PTH that could lead to increased myocardial
susceptibility to ischaemia or an increased risk for heart failure
of non-ischaemic origin. However, proof of a causal role for PTH
in cardiovascular disease is still lacking. Actually, lowering of
PTH might in parallel induce lowering of other factors (i.e.
FGF23), which are by themselves propelling cardiovascular mor-
bidity and mortality [69]. Some experimental research data even
point towards protection by PTH: application of PTH in rodent
myocardial infarction models led to reduction in infarction size
and improved cardiac function parameters [70]. Better recruit-
ment of stem cells via PTH-induced mobilization might serve as
an explanation for these remarkable observations [71].
CONTROL OF SHPT BY OLD AND NEW
VITAMIN D COMPOUNDS
True deficiency, or relative insufficiency, of 25OHD is highly
prevalent among patients with CKD or ESRD and is a critical
component in the pathogenesis of SHPT. Accordingly, current
guidelines suggest that in the setting of CKD G3a–G5D, 25OHD
levels might be measured, and repeated testing depending on
baseline values and therapeutic interventions. They also sug-
gest that vitamin D deficiency and insufficiency be corrected us-
ing treatment strategies recommended for the general
population [1, 72].
Whereas nutritional vitamin D replacement may restore
25OHD concentration to near, or even above ‘normal’, the real
target of treating vitamin D insufficiency is and will remain the
successful treatment of SHPT, which is largely unaffected by
nutritional vitamin D.
Ranged against that is softer evidence for the usefulness of
using vitamin D to treat ‘renal bone disease’ which has been
clinical custom and practice now for nearly six decades. The
practice has been in the main to use high doses of synthetic vi-
tamin D compounds, not naturally occurring ones. It is disap-
pointingly true to say that even in 2018 there is paucity of
evidence concerning the clinical benefits of vitamin D supple-
mentation to treat vitamin D insufficiency in patients with
Stages 3b–5 CKD [73].
While there are a number of studies that report the impact
of vitamin D supplementation on serum vitamin D concentra-
tions and some variable evidence of serum PTH concentration
suppression, there has been much less focus on hard endpoint
analysis (e.g. fractures, hospitalizations and overall mortality).
In 2018, with the practice pattern changes of widespread clinical
use of vitamin D and widespread supplementation of cholecal-
ciferol or ergocalciferol by patients, it is now next to impossible
to run a placebo-controlled trial over a decent period of time to
explore relevant clinical outcomes. In this challenging situation,
we need to ask what it is we are trying to achieve here for our
patients, and how best to balance potential benefits with poten-
tial harm [74].
Extended-release calcifediol (ERC) 30mg capsules were recently
approved by the United States Food and Drug Administration for
the treatment of SHPT in adults with Stages 3–4 CKD and vitamin
D insufficiency (serum total 25OHD <75 nmol/L) [75]. Calcifediol is
25-hydroxyvitamin D3, a prohormone of the active calcitriol (1,
25-dihydroxyvitamin D3). ERC capsules have a lipophilic fill,
which gradually releases calcifediol, corrects vitamin D insuffi-
ciency and increases serum calcitriol, and thereby suppresses
production of PTH in CKD patients without perturbing normal vi-
tamin D and mineral metabolism. Randomized clinical trials
(RCTs) have demonstrated that non-modified nutritional vitamin
D is ineffective for treating SHPT (when used in conventional
doses, up to the equivalent of around 4000 IU/day) whereas vita-
min D receptor activators can very easily and significantly correct
elevated PTH concentrations, but with increased risk of hypercal-
caemia and hyperphosphataemia [74]. ERC offers healthcare pro-
fessionals a new treatment option that has been demonstrated in
RCTs to be safe and effective for controlling SHPT without mean-
ingfully increasing serum concentrations of calcium or phospho-
rus [75, 76].
OLD AND NEW CALCIMIMETICS
Calcimimetics are established treatments for SHPT. They in-
crease the sensitivity of CaSR leading to the decrease of the
set-point for systemic calcium homeostasis. This enables a de-
crease in plasma PTH levels, and consequently of calcium lev-
els. Cinacalcet was the first calcimimetic approved for clinical
use and effectively reduces PTH and improves biochemical con-
trol of mineral and bone disorders in dialysis patients [77].
Three randomized controlled trials analysed the effects of
treatment with cinacalcet on vascular calcification, bone
histology and cardiovascular mortality and morbidity [78–80].
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The Evaluation of Cinacalcet Hydrochloride Therapy to Lower
Cardiovascular Events (EVOLVE) trial [81] was a RCT enrolling
3883 haemodialysis patients with moderate to severe SHPT
assigned to receive cinacalcet or placebo. All patients could si-
multaneously receive conventional treatment including phos-
phate binders and vitamin D sterols. The primary composite
endpoint was time until death, myocardial infarction, hospitali-
zation for unstable angina, heart failure or a peripheral vascular
event. Regrettably, this large RCT could not demonstrate im-
provement of hard outcomes with cinacalcet based on
intention-to-treat analysis. However, the interpretation of a
negative study outcome has been considered inconclusive
rather than definitive, due to significant cross-over of placebo-
treated cases to the active treatment arm.
Etelcalcetide is a new, second-generation calcimimetic ad-
ministered intravenously. Its pharmacokinetic profile allows
thrice-weekly dosing at the time of haemodialysis. It was re-
cently approved in Europe. A double-bind, double-dummy ac-
tive RCT was conducted comparing intravenous etelcalcetide
with oral placebo versus oral cinacalcet with intravenous pla-
cebo in 683 haemodialysis patients with PTH higher than
500 pg/mL [82]. The primary efficacy endpoint was non-
inferiority of etelcalcetide at achieving more than a 30% reduc-
tion from baseline in mean pre-dialysis PTH concentration.
Secondary endpoints included superiority in achieving bio-
chemical endpoints (>50% and >30% reduction in PTH) and
self-reported nausea or vomiting. Etelcalcetide was not inferior
to cinacalcet in reducing PTH concentration and also met supe-
riority criteria. The proportion of patients who achieved a
greater than 30% and 50% PTH reduction was greater for etelcal-
cetide compared with cinacalcet treatment [83]. Hypocalcaemia
was more frequent in the etelcalcetide group. Etelcalcetide did
not prove to have fewer gastrointestinal symptoms despite in-
travenous administration. Overall safety and tolerability be-
tween etelcalcetide and cinacalcet were similar. Etelcalcetide
treatment yielded more pronounced reduction in FGF23 levels
than cinacalcet. Of note, in the EVOLVE trial (using oral cinacal-
cet) a 30% reduction of FGF23 levels was associated with signifi-
cant reduction of primary composite endpoint, heart failure and
death [69]. This promising finding of calcimimetics raises the
possibility of a more pronounced impact in cardiovascular out-
comes, mediated by FGF23 reductions.
IS THERE ANY INDICATION LEFT FOR PTX IN
2018?
The 2017 update of the KDIGO guideline indicates the need for
PTX ‘in patients with CKD G3a–G5D with severe SHPT who fail
to respond to medical or pharmacological therapy’. The
strength of this recommendation, unchanged from the previous
edition, is graded 2B (‘we suggest’ with ‘moderate evidence’)
[1, 72]. Thus, PTX continues to be the last therapeutic step to
control SHPT in CKD. Since in recent years the number of drugs
available for SHPT increased, the need for PTX should progres-
sively decrease. Indeed, data from the dialysis outcomes and
practice patterns study [84] demonstrated that from 1996 to
2008 there has been a decrease in PTX rates, accompanied by an
increased prescription of vitamin D and cinacalcet. Notably, this
change of therapeutic strategy was associated with increasing
PTH values in Europe, Australia-New Zealand and North
America, but not in Japan (where PTH values were stable and
the proportion of patients at target increased). However, a more
recent study from the United States Renal Data System registry,
which included a huge number of PTX cases (32 971) recorded
between 2002 and 2011, showed that the rates of PTX have not
declined in recent years. It is interesting to notice, in this study,
that the nadir was reached in 2005, concomitant with cinacalcet
commercialization, but then increased and remained stable at
roughly 5/1000 dialysis patients by 2006 [85].
Thus, new more powerful drugs do not seem to reduce the
incidence rate of PTX for biochemical control of SHPT.
Unfortunately, available data indicate that after PTX, the bio-
chemical control of SHPT sometimes does not improve [86] or
might even worsen in the medium-long term, due to a high
prevalence of low PTH values [87]. Hyperparathyroidism after
PTX is of concern because of the assumed risk of low turnover
bone, even though bone biopsies before and after PTX are rarely
performed. A very recent prospective study, which included
only 19 patients, demonstrated that 1 year after PTX almost all
patients developed adynamic bone disease, and this was associ-
ated with a significant increment of coronary calcium content
[88]. This negative finding is partly compensated by another re-
cent study, showing lower hip fracture rates in patients who re-
ceived PTX as compared with a control group [89]. Finally,
Ishani et al. [90] reported increased hospitalization rates in the
30 days and 1-year periods following PTX, which would contrib-
ute to discourage this surgery. However, in contrast to these
findings, the vast majority of observational studies evaluating
hard clinical outcomes in the medium-long term after PTX indi-
cate improvement as compared with control cases. A large re-
cent observational study [91] including 4428 PTX cases and 4428
propensity-score matched controls from a Japanese registry
showed a statistically significantly lower all-cause and cardio-
vascular mortality in the PTX group, in the 12 months
following surgery. Despite the use of adequate methodology to
adjust for confounding, selection bias can never be excluded in
observational data analysis, which would favour the outcome
for those allowed for surgery. The need for a prospective ran-
domized trial persists for the optimal treatment of SHPT [92].
PREOPERATIVE PARATHYROID IMAGING
Whatever the surgical procedure performed, that is, subtotal
PTX or total PTX with auto-transplantation, identification by
the surgeon of all parathyroid glands is required, as outlined
above. In one recent series, 12.8% of patients had fewer than
four parathyroid glands identified at surgery and this was asso-
ciated with the risk of persistent SHPT [93]. This is consistent
with a large retrospective analysis showing that in 10% of op-
erated patients, serum PTH levels at 1 month remained elevated
(897 pg/mL) [86]. Difficulty in identifying all parathyroid glands
is also associated with a higher risk of surgical complications,
such as bleeding, haematoma, infection and injury to the recur-
rent laryngeal nerve [94].
Ultrasound is a useful and widely used preoperative imaging
technique. However, even in experienced hands, ultrasound
has limitations, mainly due to its inability to detect ectopic
parathyroid glands, such as retro-tracheal, retro-oesophageal or
mediastinal glands [95].
99mTc-sestamibi scintigraphy has higher sensitivity at
detecting ectopic parathyroid glands than ultrasound [96, 97].
Moreover, hybrid gamma cameras now allow delineating the
precise anatomical position of ectopic glands by fusing three-
dimensional 99mTc-sestamibi images with computerized to-
mography (CT) cross-sectional images (single photon emission
computerized tomography (SPECT)/CT) [98]. In the neck area,
various protocols have been proposed to differentiate parathy-
roid lesions from the thyroid gland. The highest sensitivity is
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obtained through dual-tracer imaging using 99mTc-sestamibi þ
123-iodine, with image subtraction [98, 99].
Besides depicting ectopic and supernumerary glands,
99mTc-sestamibi scanning can offer functional information in
SHPT and tertiary hyperparathyroidism that can be helpful to
select the remnant parathyroid tissue with the least autonomy,
thus reducing the risk of recurrence [96, 100, 101].
Recurrent SHPT can be due to hyperplasia of remnant tissue
after subtotally resected parathyroid gland or autograft, a super-
numerary parathyroid gland, or both [102]. Reoperation for per-
sistent or recurrent SHPT generally is a difficult procedure with
a higher risk of complications than initial surgery. A combina-
tion of imaging techniques (ultrasound, 99mTc-sestamibi/io-
dine-123 subtraction, CT, magnetic resonance imaging (MRI))
is necessary to localize the offending lesion with enough
certainty.
The clinical utility of radiopharmaceuticals labelled with iso-
topes and used in positron-emitting tomography (PET), such as
the amino acid 11C-methionine or the lipid tracer 18F-fluorocho-
line, is also being investigated [103, 104]. Large series comparing
18F-fluorocholine PET/CT (or PET/MR) with state-of-the-art
99mTc-sestamibi/iodine-123 subtraction scintigraphy in SHPT
are warranted (Figure 3).
PERSISTENT HYPERPARATHYROIDISM AFTER
RENAL TRANSPLANTATION
Successful kidney transplantation corrects the metabolic abnor-
malities responsible for SHPT. PTH levels show a biphasic de-
cline after successful renal transplantation: an initial rapid drop
(by 50%) during the first 3–6 months, attributed to a reduction
of the parathyroid functional mass, followed by a more gradual
decline. The long lifespan of parathyroid cells (approximately
20 years) contributes to the very slow involution of the hyper-
plastic parathyroid glands after renal transplantation [105].
Parathyroid hyporesponsiveness (resistance), conversely, rap-
idly wanes after renal transplantation, parallel to the recovery
of renal function, giving rise to the frequently encountered
hypophosphataemia after kidney transplantation [13].
There is wide variation in the reported prevalence of post-
transplant HPT, ranging between 10% and 66%. This huge
variation may be explained at least partly by differences in diag-
nostic criteria, differences in study era and differences in inter-
val since transplantation. A long dialysis vintage and severe
SHPT at the time of transplantation reflected by high levels of
PTH, calcium, phosphorus, and/or tAP or need for calcimimetic
therapy confer an increased risk for persistent HPT [105]. After
transplantation, suboptimal graft function, immunosuppressive
drug therapy, metabolic acidosis, hyperphosphatoninism and
low vitamin D levels may also increase PTH secretion and con-
tribute to post-transplant HPT [105].
It should be emphasized that post-transplant HPT is the
composite of truly persistent HPT and de novo SHPT. Estimating
the relative contribution of these two components to high PTH
levels observed in the individual patient may prove difficult. In
general, persistent HPT prevails in the early post-transplant pe-
riod while de novo SHPT will become more prominent as kidney
transplant function declines. While persistent HPT by definition
is maladaptive and may contribute to specific post-transplant
complications such as hypercalcaemia [106], hypophosphatae-
mia [107, 108], (cortical) bone loss [109], fractures [110, 111] and
nephrocalcinosis [112], de novo SHPT may be appropriate to the
declining transplant function. Consequently, patients with a
FIGURE 3: 18F-fluorocholine PET/CT of parathyroid glands. 18F-fluorocholine PET/CT (contrast-enhanced CT) in a patient with PHPT and doubtful results on 99mTc-ses-
tamibi scintigraphy. PET, CT and PET/CT images are displayed in axial (A, B and G), coronal (C, D and E) and sagittal (H, I and J) views, as well as PET maximum-intensity
projection (F). Choline-avid hyperfunctioning parathyroid gland is seen at upper pole of left thyroid lobe (arrow). Neck ultrasound confirmed presence of hypoechoic 10
 5  12 mm nodule behind left upper pole of thyroid. Adapted from Hindie´ et al. [102].
8 | P.A. Ure~na-Torres et al.
Downloaded from https://academic.oup.com/ckj/advance-article-abstract/doi/10.1093/ckj/sfy061/5056879
by guest
on 21 July 2018
(predominant) persistent HPT phenotype may be hypothesized
to benefit most from PTH suppressive therapy. Calcimimetics,
nutritional and active vitamin D (analogues) and PTX may all be
considered in these patients. Calcimimetics effectively con-
trolled hypercalcaemia in patients with post-transplant HPT
but, opposite to PTX [113] and paricalcitol [114], failed to demon-
strate a beneficial impact on bone mineral density [115]. Bone
biomarkers [116], imaging techniques and ultimately bone his-
tomorphometry [117] may help identifying patients that will
benefit most from PTH-lowering therapy.
CONCLUSIONS AND PERSPECTIVES
A broad range of aspects related to PTH biology and pathology in
CKD was covered during the PTH day, where many different spe-
cialties gathered. As outlined above, exciting, and even more im-
portant, highly clinically relevant new insights about PTH
biology, its measurement, classical and off-target effects, contin-
uously emerge from ongoing basic and clinical research, even to-
day. Recent data suggest that the skeletal action of PTH in early
CKD stages to the steadily increasing activation of PTH1R may be
a key one, and the therapeutic strategies to decrease PTH levels
at these stages might not be recommended. Of high relevance to
patients with advanced CKD stages, complicated by SHPT, ongo-
ing efforts to improve and fine-tune treatment, indeed broadened
the therapeutic armamentarium. This is exemplified by the dis-
covery, and subsequent targeting by drugs, of the CaSR, which
are now developed into the recently released second-generation
calcimimetics. Insights into the regulatory role of the FGF23 and
Klotho on PTH release may also eventually be applied in clinical
practice, as pharmaco-interventions on this recently discovered
integrated system are at their dawn. Even the first available med-
ical treatment for SHPT, vitamin D therapy, is about to undergo a
revival, as the kinetic profile of a metabolic form of vitamin D for
oral use has been modified by ERC, with promising preliminary
efficacy and safety. For a long time, surgical treatment has been a
more or less definite solution for unremitting SHPT. A major
drawback of both subtotal PTX and total PTX with auto-
transplantation has been, besides early surgical complications,
the difficulty in estimating the amount of parathyroid tissue to
remove, frequently leading to persistent HPT or iatrogenic HPT
inducing adynamic bone disease. During the PTH day the most
recent imaging and functional techniques, combining the use of
dedicated tracers and high-resolution imaging, were summa-
rized. These techniques hold promise to future better ‘dosing’ of
surgical treatment of SHPT.
In addition to the advances above, patient-tailored
approaches may eventually become feasible. This may in the
future be achieved by deciphering in an individual patient to
what extent SHPT contributes not only to bone disease, but also
to cardiac dysfunction and even cognitive function, as recent
data suggests a role for PTH in these morbidities, which highly
impact on quality of life.
All in all, the comprehensive update on PTH in CKD as pre-
sented in Paris, September 2017 during the ERA-EDTA CKD-MBD
Working Group meeting, reinforced the importance of this hor-
monal system, revived interest and holds promise to further
improvements in care for our patients.
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